|
1.
|
Małecki R, Zdrojowy K and Adamiec R:
Thromboangiitis obliterans in the 21st century - a new face of
disease. Atherosclerosis. 206:328–334. 2009.PubMed/NCBI
|
|
2.
|
von Winiwarter F: Über eine eigenthümliche
form von endarteritis und endophlebitis mit gangrän des fusses.
Arch Klin Chir. 23:202–206. 1879.(In German).
|
|
3.
|
Buerger L: Thrombo-angiitis obliterans: a
study of the vascular lesions leading to presenile spontaneous
gangrene. Am J Med Sci. 136:567–580. 1908. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kurata A, Nonaka T, Arimura Y, Nunokawa M,
Terado Y, Sudo K and Fujioka Y: Multiple ulcers with perforation of
the small intestine in Buerger’s disease: a case report.
Gastroenterology. 125:911–916. 2003.PubMed/NCBI
|
|
5.
|
Arkkila PE: Thromboangiitis obliterans
(Buerger’s disease). Orphanet J Rare Dis. 1:142006.
|
|
6.
|
Olin JW: Thromboagiitis obliterans
(Buerger’s disease). N Engl J Med. 343:864–869. 2000.
|
|
7.
|
Pereira de Godoy JM and Braile DM:
Buerger’s disease and anticardiolipin antibodies. J Cardiovasc Med
(Hagerstown). 10:792–794. 2009.
|
|
8.
|
Olin JW, Young JR, Graor RA, Ruschhaupt WF
and Bartholomew JR: The changing clinical spectrum of
thromboangiitis obliterans (Buerger’s disease). Circulation.
82(Suppl): IV3–IV8. 1990.PubMed/NCBI
|
|
9.
|
de Godoy JM, de Godoy MF and Braile DM:
Recurrent thrombosis in patients with deep vein thrombosis and/or
venous thromboembolism associated with anticardiolipin antibodies.
Angiology. 57:79–83. 2006.
|
|
10.
|
Patwa JJ and Krishnan A: Buerger’s disease
(thromboangiitis obliterans) - Management by Ilizarov’s technique
of horizontal distraction. A retrospective study of 60 cases.
Indian J Surg. 73:40–47. 2011.
|
|
11.
|
Darnige L, Helley D, Fischer AM, Emmerich
J, Smadja DM and Fiessinger JN: Platelet microparticle levels: a
biomarker of thromboangiitis obliterans (Buerger’s disease)
exacerbation. J Cell Mol Med. 14:449–451. 2010.PubMed/NCBI
|
|
12.
|
Lawall H, Bramlage P and Amann B:
Treatment of peripheral arterial disease using stem and progenitor
cell therapy. J Vasc Surg. 53:445–453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lee T, Seo JW, Sumpio BE and Kim SJ:
Immunobiologic analysis of arterial tissue in Buerger’s disease.
Eur J Vasc Endovasc Surg. 25:451–457. 2003.PubMed/NCBI
|
|
14.
|
Slavov ES, Stanilova SA, Petkov DP and
Dobreva ZG: Cytokine production in thromboangiitis obliterans
patients: new evidence for an immune-mediated inflammatory
disorder. Clin Exp Rheumatol. 23:219–226. 2005.
|
|
15.
|
Eichhorn J, Sima D, Lindschau C, Turouski
A, Schmidt H, Schneider W, Haller H and Luft FC: Antiendothelial
cell antibodies in thromboangiitis obliterans. Am J Med Sci.
315:17–23. 1998. View Article : Google Scholar
|
|
16.
|
Saito Y, Sasaki K, Katsuda Y, Murohara T,
Takeshita Y, Okazaki T, Arima K, Katsuki Y, Shintani S, Shimada T,
et al: Effect of autologous bone-marrow cell transplantation on
ischemic ulcer in patients with Buerger’s disease. Circ J.
71:1187–1192. 2007.
|
|
17.
|
Wang Z, Liu LQ, Ling HZ and Yang JM: Value
of serum anti-neutrophil cytoplasmic autoantibodies and
anti-vascular endothelial cell antibodies in diagnosis of erythema
nodosum. China Trop Med. 8:1554–1555. 2008.
|
|
18.
|
Takanashi T, Horigome R, Okuda Y, Nose M,
Matsuda M and Ikeda S: Buerger’s disease manifesting nodular
erythema with livedo reticularis. Intern Med. 46:1815–1819.
2007.
|
|
19.
|
Wysokinski WE, Kwiatkowska W, Maslowski L,
Witkiewicz W and Kowal-Gierczak B: Buerger’s disease in two
brothers: iliac artery occlusion by thromboangiitis obliterans -
case reports. Angiology. 49:409–414. 1998.
|
|
20.
|
Chen Z, Takahashi M, Naruse T, Nakajima T,
Chen YW, Inoue Y, Ishikawa I, Iwai T and Kimura A: Synergistic
contribution of CD14 and HLA loci in the susceptibility to Buerger
disease. Hum Genet. 122:367–372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Isner JM, Baumgartner I, Rauh G,
Schainfeld R, Blair R, Manor O, Razvi S and Symes JF: Treatment of
thromboangiitis obliterans (Buerger’s disease) by intramuscular
gene transfer of vascular endothelial growth factor: preliminary
clinical results. J Vasc Surg. 28:964–973. 1998.
|
